|
Synonyms: CPI-006 | CPI006 | CPX-006 [1] | CPX006
Compound class:
Antibody
Comment: Mupadolimab (CPI-006) is a humanised IgG1-κ anti-CD73 (Ecto-5'-Nucleotidase; NT5E) monoclonal antibody that was developed by Corvus Pharmaceuticals as an immunostimulant, originally for oncology use. It functionally inhibits production of immunosuppressive adenosine in the tumour microenvironment, plus binding to CD73 on B cells leads to their activation (including increased antibody production). Corvus had initiated clinical investigation of mupadolimab for potential benefit in COVID-19 patients, but their phase 3 study was terminated, and as of mid-October 2021 there is no mention of this approach on their pipeline webpage (link here).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Griffin EP, Miller RA, Frey GJ, Chang HW. (2017)
Humanized anti-cd73 antibodies. Patent number: WO2017100670A1. Assignee: Corvus Pharmaceuticals. Priority date: 09/12/2015. Publication date: 15/06/2017. |
